A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different
types of solid tumors. It will also find out what side effects may occur. A side effect is
anything the drug does besides treating cancer.